The Krystal-10 study did not meet primary endpoints in 461 patients with KRAS G12C-mutated metastatic colorectal cancer, raising questions about the drug's path to full FDA approval. (Fierce Pharma)
KRAS G12C inhibitor Krazati fails confirmatory phase 3 trial
The CRC Digest